Navigation Links
One Gene May Be Key to Myeloma
Date:6/23/2008

The discovery holds promise as a treatment target for this diverse disease, experts say

MONDAY, June 23 (HealthDay News) -- Cancerous myeloma cells are so "addicted" to a gene known as IRF4, they simply can't live without it, new research has revealed.

Reducing the activity of the gene by only 50 percent is enough to kill myeloma cells without compromising other healthy activities, said scientists reporting in the current issue of Nature.

"This pathway is so critical to the growth of myeloma that, potentially, if you turn it off, you've found a chink in the armor," said Dr. Bart Kamen, executive vice president and chief medical officer at The Leukemia & Lymphoma Society.

The gene could present a target for future drug development.

"IRF4 is absolutely a target in myeloma. This is not an easy target but not an impossible target," said Dr. Louis Staudt, senior author of the paper and chief of the Lymphoid Malignancies Section, Metabolism Branch, Center for Cancer Research at the U.S. National Cancer Institute.

"It's obviously a little bit away, but we have the ability to fairly quickly figure out how to block [genes]," added Dr. Mitchell Smith, head of the lymphoma service at Fox Chase Cancer Center in Philadelphia.

Multiple myeloma, a cancer of the white blood cells, primarily affects older adults and, partly for that reason, often doesn't have a good prognosis.

What's more, there are least seven different "flavors" of multiple myeloma, each having its own unique genetic abnormalities, Staudt said. "One worries that would mean we'd need different drugs for each of these."

While there has been an explosion in new drugs to treat the disease over the past five to 10 years, there is still no cure, Smith said.

The authors took advantage of a genetic screen devised several years ago. This "Achilles' heel screen" uses RNA interference to spot part
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Emory researchers identify signaling protein for multiple myeloma
2. Human C-reactive protein regulates myeloma tumor cell growth and survival
3. Gene profiling can single out the worst cases of multiple myeloma and guide therapy
4. Gene Test Could Boost Myeloma Treatment
5. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
6. Thalidomide Improves Outcomes for Older Myeloma Patients
7. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
8. Studies attribute recent increase in multiple myeloma survival to novel therapies
9. Drug Combo Boosts Multiple Myeloma Survival
10. Penns Abramson Cancer Center part of major phase III study for myeloma
11. Drug combination effective against multiple myeloma, researchers show
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
One Gene May Be Key to Myeloma
One Gene May Be Key to Myeloma
(Date:8/29/2008)... AMD presents Telemedicine... leadership and State delegations as a possible so... N.Chelmsford, MA (PRWEB) August ...essage offered by the speakers at the Democratic N...initiative to resolve our national health care iss...
(Date:8/29/2008)... http://www.aronowitzmd.c...witz, has respected experience in plastic surgery .... Special consideration may be necessary for thes...d staff have an established specialty of procedure... Los Angeles, CA (PRWEB) August 29, 2008 -- Baria...
(Date:8/28/2008)...unction improved even after conventional therapy, ...hDay News) -- Working out on a treadmill improves ...vived a stroke and gone through the usual rehabili...ss two problems these patients have," said study r...l neurology and neurorehabilitation at the Univers...
(Date:8/28/2008)... Dr. Lawyer will lead clinical efforts of the Mary.../PRNewswire/ -- KePRO, a national medical,manageme...e position of,Medical Director. Dr. Lawyer will ov...being performed in KePRO,s Hunt Valley, Maryland H...entire medical career in Maryland," said,Alice Sto...
Breaking Medicine News(10 mins):Health News:AMD Global Telemedicine Inc. Invited to Attend Democratic National Convention 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:Treadmill Workouts Help Stroke Survivors 2Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2
...ment Binding Protein (ChREBP) results in reduction...in and prevention of// normally obese mice from be...searchers at the University of Texas, Katsumi Iizu...e UT Southwestern Medical Center, in Dallas. They...
...an increased risk of developing lymphoma and leuke...ses a lot of joint pain does have the risk of canc...gs (DMARDs) – including tumor necrosis factor alph...gic DMARD may play a role in this. TNF blockers, ...
...y to be published in the September 2006 issue of t...f miscarriage in pregnant women seeking prenatal d...al abnormalities is lower than previously believed...d chorionic villus sampling (CVS)--are common pren...
...f his lungs weakens. According to researchers, ang... 8-year study was conducted on 670 men, 45 – 86 ye...ls of long-standing anger at the beginning of the ... function at the end of it. "This study is one of...
Other Medicine News:Health News:RA Drugs Not Implicated In Cancer 2Health News:Prenatal Test and Miscarriage 2Health News:Prenatal Test and Miscarriage 3
(Date:8/27/2008)...S-52 trial, expected by mid-2009 - - Data from se...9 -, ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCal... today announced it has completed enrollment,and i...al Phase 3,randomized clinical trials of LymphoSta...c lupus erythematosus (SLE). Belimumab is being de...
(Date:8/26/2008)... landmark SYNTAX clinical trial, NATICK, Mass., A...,Corporation (NYSE: BSX ) today announced the sch...uncements at the European Society of Cardiology,Co...r 3 in Munich, Germany., The Company plans to ann...ompares percutaneous coronary intervention (PCI) u...
(Date:8/26/2008)...e/ -- Semafore Pharmaceuticals Inc.,presented data... Therapies,in Cancer in Washington, D.C., announci...hibitors that demonstrate significant anticancer,a...rietary molecular scaffold has been developed usin...f pan-PI3 kinase inhibitors,as well as isoform-sel...
(Date:8/26/2008)...wswire/ -- Healthpoint today announced,that it has...iveness of a,widely prescribed enzymatic debriding...cars. The pilot study was prompted, in part, by cl...ophic scars and beneficial healing,properties asso... "Given the findings from the peer-reviewed litera...
Breaking Medicine Technology:Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 4Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3MedThink Communications Retained by NanoBio Corporation 412 1MedThink Communications Retained by NanoBio Corporation 412 2Five Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus 28R 29 Stent Compared to Bare Metal Stent 175 1Five Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus 28R 29 Stent Compared to Bare Metal Stent 175 2Five Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus 28R 29 Stent Compared to Bare Metal Stent 175 3Five Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus 28R 29 Stent Compared to Bare Metal Stent 175 4Pop stars more than twice as likely to die an early death 411 1Pop stars more than twice as likely to die an early death 411 2Nicotine in breast milk disrupts infants sleep patterns 409 1Nicotine in breast milk disrupts infants sleep patterns 409 2Nicotine in breast milk disrupts infants sleep patterns 409 3
...eks Reinforces,Benefits of Using REVLIMID with Low...., May 15, 2007 /PRNewswire/ -- The,International ...,providing education, advocacy and support for mye...s - today said that for the,second time in four we... has demonstrated positive findings and therefore ...
...an for Asthma,Rheumatoid Arthritis and Migraines,...hree out of,four ulcerative colitis (UC) sufferers...y say not feeling well has become a normal part,of... when it comes,to their relationship with a spouse... and their emotional state (82 percent). , UC pati...
Other Medicine Technology:The International Myeloma Foundation Reports Positive Shift In,Treatment Paradigm For Patients 2The International Myeloma Foundation Reports Positive Shift In,Treatment Paradigm For Patients 3Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 2Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 3Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 4Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 5Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 6Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 7Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 8Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 9
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: